EA202090513A1 - Агенты, модулирующие функции бета-катенина, и связанные способы - Google Patents

Агенты, модулирующие функции бета-катенина, и связанные способы

Info

Publication number
EA202090513A1
EA202090513A1 EA202090513A EA202090513A EA202090513A1 EA 202090513 A1 EA202090513 A1 EA 202090513A1 EA 202090513 A EA202090513 A EA 202090513A EA 202090513 A EA202090513 A EA 202090513A EA 202090513 A1 EA202090513 A1 EA 202090513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
catenin
beta
functions
related methods
agents modulating
Prior art date
Application number
EA202090513A
Other languages
English (en)
Inventor
Джерард Хилински
Со Юн Шим
Мэттью Рейсер Паттон
Джон Хэнни Макги
Паула Ортет
Грегори Л. Вердин
Original Assignee
Фог Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фог Фармасьютикалз, Инк. filed Critical Фог Фармасьютикалз, Инк.
Publication of EA202090513A1 publication Critical patent/EA202090513A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Среди прочего, данное описание обеспечивает технологии для модулирования функций бета-катенина. В некоторых вариантах осуществления данное описание относится к сшитым пептидам, которые взаимодействуют с бета-катенином. В некоторых вариантах осуществления предложенные сшитые пептиды взаимодействуют с бета-катенином в аксинсвязывающем сайте бета-катенина. В некоторых вариантах осуществления данное описание обеспечивает соединения, композиции и способы для предотвращения и/или лечения патологических состояний, расстройств и заболеваний, которые связаны с бета-катенином.
EA202090513A 2017-09-07 2018-09-07 Агенты, модулирующие функции бета-катенина, и связанные способы EA202090513A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555519P 2017-09-07 2017-09-07
PCT/US2018/050102 WO2019051327A2 (en) 2017-09-07 2018-09-07 BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS

Publications (1)

Publication Number Publication Date
EA202090513A1 true EA202090513A1 (ru) 2020-08-24

Family

ID=65635271

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090513A EA202090513A1 (ru) 2017-09-07 2018-09-07 Агенты, модулирующие функции бета-катенина, и связанные способы

Country Status (14)

Country Link
US (2) US11198713B2 (ru)
EP (1) EP3678683A4 (ru)
JP (1) JP2020533413A (ru)
KR (1) KR20200064075A (ru)
CN (1) CN111372942A (ru)
AU (1) AU2018329956A1 (ru)
BR (1) BR112020004555A2 (ru)
CA (1) CA3074838A1 (ru)
EA (1) EA202090513A1 (ru)
IL (1) IL273015A (ru)
MA (1) MA50101A (ru)
MX (1) MX2020002435A (ru)
SG (1) SG11202001162TA (ru)
WO (1) WO2019051327A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002435A (es) 2017-09-07 2020-09-22 Fog Pharmaceuticals Inc Agentes que modulan las funciones de beta-catenina y sus métodos.
JP2022510606A (ja) 2018-11-21 2022-01-27 エンドメット バイオサイエンシーズ，インク． 子宮内膜症を処置するための組成物および方法
WO2021041895A1 (en) * 2019-08-30 2021-03-04 Ohio State Innovation Foundation Stapled beta-catenin ligands
KR20230057350A (ko) * 2020-07-22 2023-04-28 포그 파마슈티컬스 인코포레이티드 스테이플화된 펩티드 및 이의 방법
EP4355350A1 (en) * 2021-06-08 2024-04-24 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU1207301A (en) 1999-10-15 2001-04-30 Avatar Medical, Llc Stabilized proteins
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
WO2004084809A2 (en) 2003-03-20 2004-10-07 Neuren Pharmaceuticals Ltd. Neuroprotective macrocylic compounds and methods for their use
DK1615613T3 (da) 2003-04-18 2010-03-22 Enanta Pharm Inc Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
PL1680443T3 (pl) 2003-11-05 2014-02-28 Dana Farber Cancer Inst Inc Stabilizowane alfa-helikalne peptydy i ich zastosowanie
JP2008510692A (ja) 2004-08-20 2008-04-10 ノボ ノルディスク アクティーゼルスカブ 薬学的に活性なインスリン受容体調節分子
CA2577995A1 (en) 2004-08-20 2006-02-23 Phylogica Limited Peptide inhibitors of c-jun dimerization and uses thereof
US20080064643A1 (en) 2004-12-20 2008-03-13 Paolo Carminati Myd88 Homodimerization Inhibitors
GB0511771D0 (en) 2005-06-09 2005-07-20 Novartis Ag Organic compounds
EP2489360A1 (en) 2006-11-15 2012-08-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
AU2008247606A1 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
WO2009020477A1 (en) 2007-08-06 2009-02-12 Yale University Modified miniature proteins
WO2009042237A2 (en) 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
EP2247606B1 (en) 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGATURE OF STAPLED POLYPEPTIDES
WO2010034034A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010042225A2 (en) 2008-10-10 2010-04-15 Dana Farber Cancer Institute Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
JP5731986B2 (ja) 2008-12-09 2015-06-10 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｍｃｌ−１の特異的調節の方法及び組成物
BRPI0922913A2 (pt) 2008-12-10 2015-08-18 Achillion Pharmaceuticals Inc Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral
AU2010239125B2 (en) 2009-04-22 2015-05-14 The Walter And Eliza Hall Institute Of Medical Research Structure of the C-terminal region of the insulin receptor alpha-chain and of the insulin-like growth factor receptor alpha-chain
WO2010132869A2 (en) 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2012006598A2 (en) 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
DE102009032902A1 (de) 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induktion von α-Helix-Konformationen in Proteinen und Peptiden
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CA2787784A1 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
WO2011146973A1 (en) 2010-05-25 2011-12-01 Monash University Insulin analogues
US8957026B2 (en) * 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
AU2011325910B2 (en) 2010-11-12 2016-03-24 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
WO2012082891A1 (en) 2010-12-14 2012-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptide inhibitors of wnt pathway
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
US10703785B2 (en) * 2011-04-15 2020-07-07 Dana-Farber Cancer Institute, Inc. Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9
US20140256912A1 (en) 2011-06-17 2014-09-11 President And Fellows Of Harvard College Stabilized Variant MAML Peptides and Uses Thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
EP2766355B1 (en) 2011-10-11 2020-12-23 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
EP2858661B1 (en) 2011-12-29 2020-04-22 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
CA2868081C (en) 2012-03-20 2021-01-05 Loren D. Walensky Inhibition of mcl-1 and/or bfl-1/a1
WO2014047673A1 (en) 2012-09-25 2014-04-03 The Walter And Eliza Hall Institute Of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
ES2874525T3 (es) 2012-09-26 2021-11-05 Harvard College Péptidos grapados bloqueados con prolina y usos de los mismos
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
WO2014110420A1 (en) 2013-01-10 2014-07-17 Noliva Therapeutics Llc Peptidomimetic compounds
KR20150131244A (ko) 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
US10106590B2 (en) 2013-03-15 2018-10-23 Dana-Farber Cancer Institute, Inc. BH4 stabilized peptides and uses thereof
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
AU2014227824B2 (en) 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
BR112015031277A2 (pt) 2013-06-14 2017-09-19 Harvard College Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
EP3052520A4 (en) 2013-10-01 2017-12-06 President and Fellows of Harvard College Stabilized polypeptides and uses thereof
IL288147B2 (en) 2014-05-21 2024-03-01 Harvard College RAS inhibitory peptides and their uses
AU2016232833A1 (en) 2015-03-18 2017-10-12 Dana-Farber Cancer Institute, Inc. Selective Mcl-1 binding peptides
AU2016287754B2 (en) 2015-07-02 2021-02-25 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
US11078246B2 (en) 2015-08-28 2021-08-03 Dana-Farber Cancer Institute, Inc. Peptides binding to Bfl-1
EP3359180B1 (en) 2015-10-05 2024-05-15 WNTRX Pharmaceuticals Inc. Stabilized bcl9 peptides for treatment of aberrant wnt signaling
WO2017147283A1 (en) * 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
MX2020002435A (es) 2017-09-07 2020-09-22 Fog Pharmaceuticals Inc Agentes que modulan las funciones de beta-catenina y sus métodos.
JP2021535108A (ja) 2018-08-20 2021-12-16 フォグ ファーマシューティカルズ， インコーポレイテッド ペプチドの集団、ペプチド剤、及びその使用方法
CA3159729A1 (en) 2019-12-11 2021-06-17 Amrita Singh CHANDHOKE Technologies useful for assessing permeability
CA3172164A1 (en) 2020-03-17 2021-09-23 Gregory L. Verdine Helical stapled peptides and uses thereof
KR20230057350A (ko) 2020-07-22 2023-04-28 포그 파마슈티컬스 인코포레이티드 스테이플화된 펩티드 및 이의 방법
WO2022020651A1 (en) 2020-07-22 2022-01-27 Fog Pharmaceuticals, Inc. Amino acids
EP4355350A1 (en) 2021-06-08 2024-04-24 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
JP2020533413A (ja) 2020-11-19
BR112020004555A2 (pt) 2020-09-24
WO2019051327A2 (en) 2019-03-14
KR20200064075A (ko) 2020-06-05
CN111372942A (zh) 2020-07-03
CA3074838A1 (en) 2019-03-14
IL273015A (en) 2020-04-30
MX2020002435A (es) 2020-09-22
US11198713B2 (en) 2021-12-14
US20220213154A1 (en) 2022-07-07
EP3678683A2 (en) 2020-07-15
WO2019051327A3 (en) 2019-04-18
SG11202001162TA (en) 2020-03-30
US11834482B2 (en) 2023-12-05
US20200247858A1 (en) 2020-08-06
EP3678683A4 (en) 2021-07-14
AU2018329956A1 (en) 2020-08-20
MA50101A (fr) 2020-07-15

Similar Documents

Publication Publication Date Title
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201991598A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA201991599A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201891909A1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
EA201991600A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
EA201691541A1 (ru) Новые анти-baff антитела
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA202090312A1 (ru) Спироциклические соединения и способы их получения и применения
EA202092748A1 (ru) Модуляторы экспрессии apol1
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
EA202091655A1 (ru) Композиции и способы лечения нарушений сетчатки
EA201791937A1 (ru) Противовоспалительные полипептиды